REG - EKF Diagnostics Hldg - Director/PDMR Shareholding

EKF Diagnostics HoldingsAnnouncement

25/03/2024 17:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240325:nRSY2182Ia&default-theme=true

RNS Number : 2182I  EKF Diagnostics Holdings PLC  25 March 2024

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

PDMR/Director Dealings

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces that the Board of EKF has been informed that on Friday 22
March 2024, certain funds connected to Christopher Mills, Non-Executive
Director, purchased a total of 100,000 ordinary shares of 1 pence each in the
Company ("Ordinary Shares") at a price of 25.78 pence per Ordinary Share.

 

Following this transaction, Christopher Mills' total direct and indirect
interest in the Company is 132,350,000 Ordinary Shares, representing
approximately 29.169% of the total voting rights over the Company's issued
share capital.

 

The Notification of Dealing Form required in accordance with UK MAR is set out
below as is the Standard form for notification of major holdings received by
EKF today.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name

                                                                   Harwood Capital LLP and Harwood Capital Management (Gibraltar) Ltd, (the

                                                            "Investment Managers")

 2    Reason for the notification

 a)   Position/status                                              Christopher Mills is the Non-Executive Director of the issuer and Chief

                                                            Executive of the Investment Managers

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         EKF Diagnostics Holdings plc

 b)   LEI                                                          213800DXTF3EAUK1AR05

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of 1 pence each

      Identification code                                          GB0031509804

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                        Price(s)             Volume(s)
                                                                                        25.78p               100,000

 d)   Aggregated information

      - Aggregated volume                                          N/A single transaction

      - Price

 e)   Date of the transaction                                       22 March 2024

 f)   Place of the transaction                                     London Stock Exchange, AIMX

 

 EKF Diagnostics Holdings plc                              www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                             Tel: +44 (0)29 2071 0570

 Singer Capital Markets (Nominated Adviser & Broker)                                     Tel: +44 (0)20 7496 3000
 Aubrey Powell / Oliver Platts

 Walbrook PR Limited            Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About EKF Life Sciences

 

EKF Life Sciences is a specialist global manufacturer of high-quality enzymes
and custom products for use in diagnostic, pharmaceutical, and industrial
applications.

 

EKF Life Sciences is at the forefront of supporting global demand in precision
fermentation, enzyme applications and research, providing innovative
biotechnology solutions to deliver advancements in healthcare and medicine.

 

Utilising its unique technical expertise, the EKF Life Sciences uses precision
microbial fermentation and advanced downstream processes to isolate and
deliver the highest quality enzymes and biomolecules that have been specially
engineered to customer specifications.

 

EKF Life Sciences has two state-of-the-art GMP manufacturing facilities,
located within close proximity, in Elkhart and South Bend Indiana, one the
US's major life sciences and industrial hotspots. It operates to the highest
regulatory standards under cGMP principles, FDA certification and ISO 13485
Quality Program. The facilities include bioreactors ranging from 5L to
14,500L, enabling it to offer an end-to-end service from
bench/proof-of-concept through to full scale commercial production, providing
its customers with desired yields, precision at scale and cost-efficiency.

 

EKF Lifesciences is also one of the market leaders for the supply of β-HB, a
reagent used to detect ketones for patients suffering from diabetic
ketoacidosis, as well as many other clinical applications.

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·    Point-of-Care analysers in the key areas of Hematology and Diabetes,
as well as Central Laboratory products including clinical chemistry reagents,
analysers and centrifuges.

 

·      Life Sciences services provide specialist manufacture of enzymes
and custom products for use in diagnostic, food and industrial applications,
as well as other higher value Contract Manufacturing services.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBLGDXCUDDGSU